LEXEO Therapeutics
PublicLEXEO Therapeutics is now publicly traded
The data on this page reflects LEXEO Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 7, 2023
Last Round
Follow-on Offering
Oct 20, 2025
Total Funding Raised
$617.4M
Company Overview
Lexeo Therapeutics (NAS: LXEO) is a biotechnology company specializing in clinical-stage genetic medicines aimed at revolutionizing disease treatment through innovative science and targeted gene therapies for hereditary and acquired diseases with high unmet needs.
Sector
Healthcare
AI Layer
Non-AI
Keywords
LEXEO Therapeutics Comparables
Compare LEXEO Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 70% | |
| Myrtelle Inc. | 57% | |
| Minoryx Therapeutics | 55% | |
LEXEO Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Oct 20, 2025 | ||||
| Private Placement | May 28, 2025 | ||||
| Private Placement | Mar 13, 2024 | ||||
| IPO | Nov 7, 2023 | ||||
| Series B | Sep 9, 2021 | ||||
Series A | Jan 7, 2021 |
LEXEO Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Baird | Follow-on Offering |
| Lundbeck Foundation | Series B, Series A |
| Longitude Capital | Series B, Private Placement, Series A |
| Surveyor Capital | Private Placement |
| Janus Henderson Group | Series B, Series A, Private Placement |
| ADAR1 Capital Management | Private Placement |
| Balyasny Asset Management L.P. | Follow-on Offering |
LEXEO Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
